The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 13 rounds in the feed, most often at Series A and in Biotech.
Corporate venture armomegafunds.comRounds from 2017-05-22 to 2026-09-23
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Anaconda Biomed A Barcelona stroke-device company | Funding round Verified against 4 of 18 sources | $56M | 2026-09-23 | [ LEAD ] |
Vaderis Therapeutics Breakthrough therapies for patients with Hereditary Hemorrhagic Telangiectasia (HHT) and other rare vascular diseases. | Series B Verified against 1 of |
| $152M |
| 2026-08-11 |
| [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A ext. Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $197M financing total | 2026-02-24 | [ LEAD ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $160M | 2026-01-08 | [ LEAD ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-11-17 | [ PART ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $132M | 2025-07-29 | [ PART ] |
Callio Therapeutics Dual-payload antibody-drug conjugates (ADCs) for cancer treatment. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $187M | 2025-03-03 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-10 | [ PART ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $90M | 2023-12-07 | [ PART ] |
ArtBio ARTBIO develops alpha radioligand therapies focused on cancer treatment aimed at healthcare providers and patients. | Seed Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $23M | 2023-06-21 | [ PART ] |
Artios Pharma Artios is a clinical-stage oncology company developing new medicines targeting DNA damage response pathways in cancer for patients with limited treatment options. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $153M | 2021-07-27 | [ LEAD ] |
Anaconda Biomed A Barcelona stroke-device company | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $16.9M | 2017-05-22 | [ LEAD ] |